Search Result

Results for "

obesity

" in MCE Product Catalog:

By Targets:	Fat Mass and Obesity-associated Protein (FTO) (9) 11β-HSD (9) 5-HT Receptor (5) Acetyl-CoA Carboxylase (1) Acyltransferase (6) Adenosine Receptor (1) Adrenergic Receptor (7) Akt (1) Aldehyde Dehydrogenase (ALDH) (1) AMPK (7) Antibiotic (3) AP-1 (1) Apoptosis (8) Aryl Hydrocarbon Receptor (1) ATP Citrate Lyase (2) Autophagy (10) Bacterial (9) Bcl-2 Family (1) Biochemical Assay Reagents (1) Bombesin Receptor (1) c-Myc (1) Calcium Channel (1) Cannabinoid Receptor (13) Carbonic Anhydrase (4) Carboxypeptidase (1) Casein Kinase (4) Caspase (1) CFTR (3) CGRP Receptor (2) Cholecystokinin Receptor (1) COX (6) CRFR (2) Cytochrome P450 (1) Dipeptidyl Peptidase (2) Dopamine Receptor (3) Dopamine Transporter (1) Drug Metabolite (1) EGFR (2) Endogenous Metabolite (34) ERK (1) Fatty Acid Synthase (FASN) (5) Ferroptosis (3) Free Fatty Acid Receptor (1) Fungal (2) G protein-coupled Bile Acid Receptor 1 (1) Galectin (1) Gap Junction Protein (5) GCGR (11) GHSR (1) GLP Receptor (8) Glucocorticoid Receptor (3) Glucosidase (3) GLUT (1) GPR119 (1) GPR139 (1) HCV (2) HIF/HIF Prolyl-Hydroxylase (2) HIV (1) HSP (1) Influenza Virus (3) Insulin Receptor (3) Interleukin Related (2) Isotope-Labeled Compounds (3) MAGL (1) MCHR1 (GPR24) (2) Melanocortin Receptor (3) Melatonin Receptor (1) Microsomal Triglyceride Transfer Protein (MTP) (1) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (6) MMP (1) Monoamine Oxidase (5) Neuropeptide Y Receptor (5) NF-κB (4) NO Synthase (1) NOD-like Receptor (NLR) (1) Opioid Receptor (1) P-glycoprotein (4) Parasite (1) PARP (1) PD-1/PD-L1 (1) PDHK (2) Phosphatase (3) Phospholipase (1) PI3K (4) Potassium Channel (6) PPAR (20) Pyruvate Kinase (1) Reactive Oxygen Species (5) Ribosomal S6 Kinase (RSK) (1) SARS-CoV (4) Ser/Thr Protease (3) Serotonin Transporter (1) Sirtuin (7) STAT (1) Stearoyl-CoA Desaturase (SCD) (2) TGF-β Receptor (2) Thyroid Hormone Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) TRP Channel (4) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (67) Cardiovascular Disease (21) Endocrinology (17) Infection (18) Inflammation/Immunology (57) Metabolic Disease (214) Neurological Disease (43)

By Targets:

Fat Mass and Obesity-associated Protein (FTO) (9)

11β-HSD (9)

5-HT Receptor (5)

Acetyl-CoA Carboxylase (1)

Acyltransferase (6)

Adenosine Receptor (1)

Adrenergic Receptor (7)

Akt (1)

Aldehyde Dehydrogenase (ALDH) (1)

AMPK (7)

Antibiotic (3)

AP-1 (1)

Apoptosis (8)

Aryl Hydrocarbon Receptor (1)

ATP Citrate Lyase (2)

Autophagy (10)

Bacterial (9)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Bombesin Receptor (1)

c-Myc (1)

Calcium Channel (1)

Cannabinoid Receptor (13)

Carbonic Anhydrase (4)

Carboxypeptidase (1)

Casein Kinase (4)

Caspase (1)

CFTR (3)

CGRP Receptor (2)

Cholecystokinin Receptor (1)

COX (6)

CRFR (2)

Cytochrome P450 (1)

Dipeptidyl Peptidase (2)

Dopamine Receptor (3)

Dopamine Transporter (1)

Drug Metabolite (1)

EGFR (2)

Endogenous Metabolite (34)

ERK (1)

Fatty Acid Synthase (FASN) (5)

Ferroptosis (3)

Free Fatty Acid Receptor (1)

Fungal (2)

G protein-coupled Bile Acid Receptor 1 (1)

Galectin (1)

Gap Junction Protein (5)

GCGR (11)

GHSR (1)

GLP Receptor (8)

Glucocorticoid Receptor (3)

Glucosidase (3)

GLUT (1)

GPR119 (1)

GPR139 (1)

HCV (2)

HIF/HIF Prolyl-Hydroxylase (2)

HIV (1)

HSP (1)

Influenza Virus (3)

Insulin Receptor (3)

Interleukin Related (2)

Isotope-Labeled Compounds (3)

MAGL (1)

MCHR1 (GPR24) (2)

Melanocortin Receptor (3)

Melatonin Receptor (1)

Microsomal Triglyceride Transfer Protein (MTP) (1)

Mineralocorticoid Receptor (1)

Mitochondrial Metabolism (6)

MMP (1)

Monoamine Oxidase (5)

Neuropeptide Y Receptor (5)

NF-κB (4)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

Opioid Receptor (1)

P-glycoprotein (4)

Parasite (1)

PARP (1)

PD-1/PD-L1 (1)

PDHK (2)

Phosphatase (3)

Phospholipase (1)

PI3K (4)

Potassium Channel (6)

PPAR (20)

Pyruvate Kinase (1)

Reactive Oxygen Species (5)

Ribosomal S6 Kinase (RSK) (1)

SARS-CoV (4)

Ser/Thr Protease (3)

Serotonin Transporter (1)

Sirtuin (7)

STAT (1)

Stearoyl-CoA Desaturase (SCD) (2)

TGF-β Receptor (2)

Thyroid Hormone Receptor (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (2)

TRP Channel (4)

VEGFR (1)

Wnt (1)

By Research Areas:

Cancer (67)

Cardiovascular Disease (21)

Endocrinology (17)

Infection (18)

Inflammation/Immunology (57)

Metabolic Disease (214)

Neurological Disease (43)

269

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas

HY-101082

N6,2′-O-Dimethyladenosine	Fat Mass and Obesity-associated Protein (FTO)	Metabolic Disease
N6,2′-O-Dimethyladenosine, a substrate of fat mass and obesity-associated gene (FTO), is a reversible modification widely occurred on varied RNA molecules. N6,2′-O-Dimethyladenosine can regulate obesity.

HY-19401

L-796568
Adrenergic Receptor Metabolic Disease

L-796568 is a β(3)-adrenergic receptor agonist. L-796568 can be used for the research of obesity.

L-796568	Adrenergic Receptor	Metabolic Disease
L-796568 is a β(3)-adrenergic receptor agonist. L-796568 can be used for the research of obesity.

HY-11083

GW-803430 GW-3430	MCHR1 (GPR24)	Metabolic Disease
GW-803430 (GW-3430) is a potent and selective melanin-concentrating hormone receptor 1 (MCH R1) antagonist with a pIC₅₀ of 9.3. GW-803430 is orally active in an animal model of obesity.

HY-44154

PSB-CB5
Others Metabolic Disease

PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity.

PSB-CB5	Others	Metabolic Disease
PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity.

HY-N0200

Albaspidin AP	Fatty Acid Synthase (FASN)	Cancer Metabolic Disease
Albaspidin AP inhibits fatty acid synthase (FAS) with an IC₅₀ value of 71.7 μM. Fatty acid synthase (FAS) is emerging as a potential therapeutic target for cancer and obesity.

HY-139994

XN methyl pyrazole
XP
Others Metabolic Disease

XN methyl pyrazole improves diet-induced obesity and induces energy expenditure in high-fat diet-fed mice.

XN methyl pyrazole XP	Others	Metabolic Disease
XN methyl pyrazole improves diet-induced obesity and induces energy expenditure in high-fat diet-fed mice.

HY-N10606

Uvagrandol	Glucosidase	Metabolic Disease
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC₅₀: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity.

HY-108196

PTP1B-IN-15	Phosphatase	Endocrinology
PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity.

HY-124758

SH-BC-893	Mitochondrial Metabolism	Cancer Metabolic Disease
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity.

HY-B0227

Ketoprofen RP-19583	COX	Metabolic Disease Inflammation/Immunology Cancer
Ketoprofen (RP-19583) is a non-steroidal anti-inflammatory agent. Ketoprofen can inhibits the activity of cyclooxygenase with IC₅₀ values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.

HY-P3462

Cagrilintide	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

HY-B0227A

Ketoprofen (lysinate) RP-19583 (lysinate)	COX	Metabolic Disease Inflammation/Immunology
Ketoprofen (RP-19583) lysinate is a non-steroidal anti-inflammatory agent. Ketoprofen lysinate can inhibit the activity of cyclooxygenase with IC₅₀ values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.

HY-150067

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀ value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity.

HY-N10428

Ganoapplanoid F	Others	Metabolic Disease
Ganoapplanoid F, a highly oxygenated lanostane triterpenoid from Ganoderma applanatum, inhibits lipid accumulation in adipocytes. Ganoapplanoid F can be used for the research of obesity.

HY-N7653

Azaleatin	Dipeptidyl Peptidase	Metabolic Disease
Azaleatin is an O-methylated flavonol isolated from Rhododendron species. Azaleatin is a dipeptidyl peptidase-IV inhibitor. Azaleatin can be used for the research of type-2 diabetes and obesity.

HY-P1432

K-(D-1-Nal)-FwLL-NH2	GHSR	Metabolic Disease
K-(D-1-Nal)-FwLL-NH2 is a high affinity, potent and inverse ghrelin receptor agonist (EC₅₀=3.4 nM, K_i=4.9 nM). K-(D-1-Nal)-FwLL-NH2 can be used for the research of obesity.

HY-P3495

Pegapamodutide
LY-2944876
GLP Receptor Metabolic Disease

Pegapamodutide (LY-2944876) is a glucagon-GLP-1 receptor agonist, and can be used in type 2 diabetes and obesity research.

Pegapamodutide LY-2944876	GLP Receptor	Metabolic Disease
Pegapamodutide (LY-2944876) is a glucagon-GLP-1 receptor agonist, and can be used in type 2 diabetes and obesity research.

HY-14690

Ecopipam SCH 39166	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Metabolic Disease Neurological Disease
Ecopipam (SCH 39166) is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with K_is of 1.2 nM and 2.0 nM, respectively. Ecopipam shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (K_i=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam can be used for the research of schizophrenia and obesity.

HY-14689

Ecopipam hydrochloride SCH 39166 hydrochloride	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Metabolic Disease Neurological Disease
Ecopipam (SCH 39166) hydrochloride is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with K_is of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrochloride shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (K_i=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrochloride can be used for the research of schizophrenia and obesity.

HY-110033

Ecopipam hydrobromide SCH 39166 hydrobromide	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Metabolic Disease Neurological Disease
Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with K_is of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (K_i=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrobromide can be used for the research of schizophrenia and obesity.

HY-150012

N-Lactoyl-Phenylalanine	Endogenous Metabolite	Endocrinology Metabolic Disease
N-Lactoyl-Phenylalanine is a blood-borne signalling metabolite and can be used for obesity research. N-Lactoyl-Phenylalanine is exercise-inducible.

HY-118949

LY255582	Opioid Receptor	Metabolic Disease
LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (K_i: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity.

HY-12841

KHK-IN-1	Others	Metabolic Disease
KHK-IN-1 (compound 8) is a selective and cell membrane permeable ketohexokinase (KHK) inhibitor (IC₅₀=12 nM; F=34%). KHK-IN-1 inhibits the production of F1P in HepG2 cell lysates (IC>sub>50=400 nM). KHK-IN-1 has potential for the study of diabetes and obesity.

HY-12841A

KHK-IN-1 hydrochloride	Others	Metabolic Disease
KHK-IN-1 hydrochloride (compound 8) is a selective and cell membrane permeable ketohexokinase (KHK) inhibitor (IC₅₀=12 nM; F=34%). KHK-IN-1 hydrochloride inhibits the production of F1P in HepG2 cell lysates (IC>sub>50=400 nM). KHK-IN-1 hydrochloride has potential for the study of diabetes and obesity.

HY-F0004

β-Nicotinamide mononucleotide β-NM; NMN	Endogenous Metabolite	Cancer Neurological Disease
β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD⁺ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity.

HY-137840

Hippuryl-L-phenylalanine	Carboxypeptidase	Cancer
Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity.

HY-14342

MK-5046	Bombesin Receptor	Metabolic Disease
MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC₅₀ and an EC₅₀ value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity.

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.

HY-113334

Turanose	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research.

HY-131515

Tri-Salicylic acid	Others	Metabolic Disease Inflammation/Immunology Cardiovascular Disease
Tri-Salicylic acid is the compound with similar properties of salicylic acid. Tri-Salicylic acid has the potential for the research of inflammation, obesity and cardiovascular diseases (extracted from patent US20170368079A1, compound III).

HY-128057

NCRW0005-F05	GPR139	Metabolic Disease Neurological Disease
NCRW0005-F05 is a potent GPR139 antagonist with an IC₅₀ value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's disease.

HY-W016868

3-Chloro-5-hydroxybenzoic acid	Others	Metabolic Disease
3-Chloro-5-hydroxybenzoic acid is a potent, orally active and selective lactate receptor GPR81 agonist, with an EC₅₀ of 16 μM for human GPR81. 3-Chloro-5-hydroxybenzoic acid exhibits favorable in vivo effects on lipolysis in a mouse model of obesity.

HY-120273

Glucocorticoids receptor agonist 3	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
Glucocorticoids receptor agonist 3 is a potent agonist of glucocorticoids receptor. Glucocorticoids receptor agonist 3 is useful to research diseases, such as obesity, diabetes, and inflammation (extracted from patent WO2000066522A1, compound 345).

HY-114702

M77976	PDHK	Metabolic Disease
M77976 is a specific ATP-competitive inhibitor of PDK4 (pyruvate dehydrogenase kinase isoforms 4), with an IC₅₀ of 648 μM. M77976 is potential for the research of obesity and diabetes.

HY-P1230

HAEGT	Dipeptidyl Peptidase GLP Receptor	Metabolic Disease
HAEGT is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity.

HY-131999

3,4,5-Trihydroxycinnamic acid decyl ester	Others	Metabolic Disease
3,4,5-Trihydroxycinnamic acid decyl ester is an excellent inhibitor of lipid absorption and accumulation, with anti-obesity properties. 3,4,5-Trihydroxycinnamic acid decyl ester is a pancreatic lipase inhibitor, with an EC₅₀ of approximately 0.9 μM.

HY-138996

GLP-1 receptor agonist 8	GCGR	Metabolic Disease
GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17).

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies.

HY-141411A

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).

HY-150607

UNC7467	Others	Others
UNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research.

HY-14791

Ibipinabant SLV319; BMS-646256	Cannabinoid Receptor	Metabolic Disease
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a K_i of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic.

HY-50861

AZD3988	Acyltransferase	Metabolic Disease
AZD3988 is an orally active diacylglycerol acyl transferase-1 (DGAT-1) inhibitor. AZD3988 has excellent DGAT-1 (human) potency with an IC₅₀ value of 0. 6 nM. AZD3988 can be used for the research of metabolic diseases such as diabetes, obesity.

HY-103238

RSVA405	AMPK STAT Autophagy	Metabolic Disease Inflammation/Immunology Neurological Disease
RSVA405 is a potent, orally active activator of AMPK, with an EC₅₀ of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity.

HY-139058

23-epi-26-Deoxyactein
27-Deoxyactein
PPAR Cancer Metabolic Disease

23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

23-epi-26-Deoxyactein 27-Deoxyactein	PPAR	Cancer Metabolic Disease
23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

HY-121827

LH21	Cannabinoid Receptor	Metabolic Disease
LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor.

HY-16434

DGAT1-IN-3	Acyltransferase	Metabolic Disease
DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC₅₀s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. DGAT1-IN-3 could be used to research of obesity, dyslipidemia, and metabolic syndrome.

HY-15756

PTP1B-IN-4	Phosphatase	Metabolic Disease
PTP1B-IN-4 is a non-competitive allosteric inhibitor of the protein tyrosine phosphatase PTP1B, with an IC₅₀ of 8 μM. PTP1B-IN-4 is potentail for the research of obesity and diabetes.

HY-138843

FTO-IN-1	Fat Mass and Obesity-associated Protein (FTO)	Cancer Metabolic Disease
FTO-IN-1 is a *fat mass and obesity-associated enzyme (FTO)* inhibitor extracted from patent WO2018157843A1, compound 32, with an IC₅₀ of <1 μM. FTO-IN-1 can be used for the research of cancer.

HY-W324220

11β-HSD1-IN-10	11β-HSD	Metabolic Disease
11β-HSD1-IN-10 (compound c3a) is a potent 11β-HSD1 inhibitor (IC₅₀=1.8 µM for human). 11β-HSD1-IN-10 can be used in studies of obesity, hyperglycemia and cognitive impairment.

HY-N2925

β-Amyrone β-Amyron	Fungal COX PPAR	Infection Metabolic Disease Inflammation/Immunology
β-Amyrone (β-Amyron) is a triterpene compound which has anti-inflammatory activity through inhibiting the expression of COX-2. β-Amyrone has antifungal activity , as well as antiviral activity against Chikungunya virus. β-Amyrone also inhibits α-glucosidase and acetylcholinesterase (AChE) activity. β-Amyrone can be used in the research of disease like inflammation, infection, and obesity.

HY-138843A

FTO-IN-1 TFA	Fat Mass and Obesity-associated Protein (FTO)	Cancer Metabolic Disease
FTO-IN-1 TFA is a *fat mass and obesity-associated enzyme (FTO)* inhibitor extracted from patent WO2018157843A1, compound 32, with an IC₅₀ of <1 μM. FTO-IN-1 TFA can be used for the research of cancer.

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Endocrinology Metabolic Disease
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.

HY-P3677

Neuropeptide Y (2-36) (porcine)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y (2-36) (porcine) is a porcine-derived neuropeptide with 97.14% homology to rat/human origin. Neuropeptide Y (2-36) (porcine) is also a rat neuropeptide receptor agonist, with EC₅₀ values of 1.2, 1.6 and 3.4 nM for receptor of Y5, Y2 and Y1 respectively. Neuropeptide Y (2-36) (porcine) can be used in studies related to obesity and eating disorders.

HY-125096

C108297	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
C108297 is a selective glucocorticoid receptor (GR) modulator (GR binding K_i 0.7 nM; GR reporter gene functional K_i 0.6 nM). C108297 attenuates obesity by reducing caloric intake and increasing lipolysis and fat oxidation, and in addition attenuates inflammation.

HY-141669

BCAT-IN-2	Others	Metabolic Disease
BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC₅₀ of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC₅₀=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.

HY-16953

JNJ 303	Potassium Channel	Neurological Disease Cardiovascular Disease
JNJ-303 is a specific delayed rectifier Kv blocker. JNJ 303 can potent block I_Ks with an IC₅₀ value of 64 nM. JNJ-303 can be used for the research of diabetes, obesity and central nervous system.

HY-117378

N-5984 KRP-204	Adrenergic Receptor	Cancer Inflammation/Immunology
N-5984 (KRP-204) is a potent and selective agonist of β3-adrenergic receptor. N-5984 has the potential for developing as one of the clinically effective drugs for obesity and diabetes mellitus.

HY-145605

Vutiglabridin HSG4112	Others	Metabolic Disease
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability.

HY-123090

11β-HSD1-IN-12	11β-HSD	Metabolic Disease
11β-HSD1-IN-12 is a 11β-HSD1 inhibitor (Example 21 in reference patent). 11β-HSD1 regenerates active glucocorticoids from inactive forms and is important in regulating intracellular glucocorticoid concentration. 11β-HSD1-IN-12 can be used in the research of obesity and metabolic syndrome.

HY-P3506

Retatrutide LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits for human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.

HY-N7687

Caulophyllogenin	PPAR	Metabolic Disease Inflammation/Immunology
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation.

HY-P1775

Carbonic anhydrase EC 4.2.1.1	Carbonic Anhydrase	Cancer Metabolic Disease Neurological Disease
Carbonic anhydrase is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy.

HY-142114

SRI-37330	Others	Metabolic Disease
SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes.

HY-147301

Resomelagon AP1189	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon induces ERK1/2 phosphorylation and Ca²⁺ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research.

HY-114911

Feprazone DA2370; Prenazone; Zepelin	COX Reactive Oxygen Species MMP	Inflammation/Immunology
Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity.

HY-15206

Glibenclamide Glyburide	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glibenclamide (Glyburide) is an orally active ATP-sensitive K⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR). Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. Glibenclamide can induce autophagy.

HY-145632

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.

HY-P3506A

Retatrutide TFA LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA inhibits for human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.

HY-143614

THR-β agonist 3	Others	Metabolic Disease
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6).

HY-143613

THR-β agonist 2	Others	Metabolic Disease
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3).

HY-133556

IQZ23	AMPK	Metabolic Disease
IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC₅₀=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.

HY-142917

THR-β agonist 4	Others	Metabolic Disease
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72).

HY-B1779

Sucrose D-(+)-Saccharose	Endogenous Metabolite	Metabolic Disease Cancer
Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al.

HY-148312

Sirtuin modulator 4	Sirtuin	Cancer Inflammation/Immunology Neurological Disease Cardiovascular Disease
Sirtuin modulator 4 (compound 12) is a sirtuin modulator. Sirtuin modulator 4 shows inhibitory effect to SIRT1 with an EC₅₀ value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.

HY-W324243

11β-HSD1-IN-9	11β-HSD	Metabolic Disease
11β-HSD1-IN-9 (compound c4a) is a potent 11β-HSD1 inhibitor with IC₅₀ values of 0.48 and 1.3 µM for human and murine 11β-HSD1, respectively. 11β-HSD1-IN-9 competitively interacts with rat 11β-HSD1. 11β-HSD1-IN-19 can be used in studies of obesity, hyperglycemia and cognitive impairment.

HY-147037

AMPK activator 7	AMPK	Metabolic Disease Cardiovascular Disease
AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC₅₀ of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension.

HY-16673

PSN632408	GPR119	Metabolic Disease
PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC₅₀=5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders.

HY-147376

hACC2-IN-1	Acetyl-CoA Carboxylase	Metabolic Disease
hACC2-IN-1 is a potent acetyl-CoA carboxylase 2 (ACC2) inhibitor, with an IC₅₀ value of 2.5 μM (hACC2). hACC2-IN-1 could be used for obesity research.

HY-18054

BVT 2733	11β-HSD	Inflammation/Immunology
BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC₅₀=96 nM) over the human enzyme (IC₅₀=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease.

HY-151193

NNMT-IN-3	Others	Cancer Metabolic Disease
NNMT-IN-3 (compound 14) is a potent and selective nicotinamide N-methyltransferase NNMT inhibitor with IC₅₀ values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. NNMT-IN-3 can be used to research obesity, type 2 diabetes, alcohol-related liver disease, cancer, sarcopenia and so on.

HY-145086

R-PSOP	Others	Metabolic Disease
R-PSOP is highly potent and selective nonpeptidic NMUR2 antagonist. R-PSOP binds to NMUR2 with the K_is of 52 and 32 nM for the human and rat NMUR2, respectively. R-PSOP shows moderate CNS penetration. R-PSOP can be used for the research of the eating disorders, obesity, pain, and stress-related disorders.

HY-P2048A

MOTS-c(human) acetate	AMPK GLUT	Metabolic Disease
MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity.

HY-P2231

Cotadutide MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).

HY-P2231A

Cotadutide acetate MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D).

HY-N3127

Orobol	Casein Kinase PI3K VEGFR	Metabolic Disease
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ).

HY-126003

ALDH1A1-IN-2	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH1A1-IN-2 is a potent inhibitor of aldehyde dehydrogenase 1a1 (aldh1a1). Aldehyde dehydrogenases (ALDH) constitute a family of enzymes that play a critical role in oxidizing various cytotoxic xenogenic and biogenic aldehydes. ALDH1A1-IN-2 has the potential for the research of cancer, inflammation, or obesity (extracted from patent WO2019089626A1, compound 295).

HY-113293

Estrone sulfate	Endogenous Metabolite	Metabolic Disease
Estrone sulfate is an endogenous metabolite present in Blood that can be used for the research of X-Linked Ichthyosis and Obesity.

HY-131448

A3334	Others	Metabolic Disease
A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC₅₀ of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH.

HY-109188

Relzomostat	Others	Metabolic Disease
Relzomostat is a methionine aminopeptidase 2 (MetAP2) inhibitor.Relzomostat may be useful for the research of obesity, type 2 diabetes, and other obesity-associated conditions.

HY-110179

PSNCBAM-1	Cannabinoid Receptor	Metabolic Disease
PSNCBAM-1 is a selective CB1 receptor allosteric antagonist with an EC₅₀ of 0.1 μM. PSNCBAM-1 can be used in the researches of obesity.

HY-145809

FASN-IN-5	Fatty Acid Synthase (FASN)	Cancer Inflammation/Immunology Metabolic Disease
FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity.

HY-W127369

1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine PC(O-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))	Endogenous Metabolite	Metabolic Disease
1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine is an endogenous metabolite present in Urine that can be used for the research of Obesity.

HY-B0218

Orlistat Tetrahydrolipstatin; Ro-18-0647	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.

HY-11076

GI 181771
Cholecystokinin Receptor Metabolic Disease Endocrinology

GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity.

HY-13012

RepSox E-616452; SJN 2511	TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.

HY-P4815

Prokineticin 2 Isoform 2 (human)	Endogenous Metabolite	Metabolic Disease Neurological Disease
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity.

HY-148322

Sirtuin modulator 5	Sirtuin	Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC₅₀ value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity.

HY-W015464

N-Isovaleroylglycine	Endogenous Metabolite	Metabolic Disease
N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-145238

FTO-IN-6
Fat Mass and Obesity-associated Protein (FTO) Others

FTO-IN-6 is a selective fat mass and obesity associated protein (FTO) inhibitor.

HY-121835

GLP-1R agonist 2	GCGR	Metabolic Disease
GLP-1R agonist 2 (compound 2) is a potent GLP-1R agonist. GLP-1R agonist 2 has the potential for the research of metabolic diseases like Type2 Diabetes and Obesity.

HY-153530

LI-2242	Others	Metabolic Disease Neurological Disease
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.

HY-139820

FTO-IN-4
Fat Mass and Obesity-associated Protein (FTO) Cancer Neurological Disease

FTO-IN-4 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
HY-139821

FTO-IN-5
Fat Mass and Obesity-associated Protein (FTO) Cancer Neurological Disease

FTO-IN-5 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).

HY-103327

MJ15	Cannabinoid Receptor	Metabolic Disease
MJ15 is a potent and selective CB1 receptor antagonist with a K_i of 27.2 pM and an IC₅₀ of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice.

HY-107542

Oleoylethanolamide N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Endogenous Metabolite PPAR	Metabolic Disease Cardiovascular Disease
Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N2302

Fucoxanthin all-trans-Fucoxanthin	Others	Cancer Metabolic Disease Inflammation/Immunology
Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

HY-107124

BMS-770767	11β-HSD	Metabolic Disease
BMS-770767 is an 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor in type 2 diabetes. 11β-HSD1 is an important enzyme that is widely expressed in liver, adipose tissue and other tissues and plays an important role in metabolic diseases such as diabetes and obesity.

HY-N4042

Hirsutenone	PI3K ERK	Cancer Inflammation/Immunology
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity.

HY-143721

SSAO inhibitor-2	Monoamine Oxidase	Metabolic Disease Cardiovascular Disease Inflammation/Immunology
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.

HY-143723

SSAO inhibitor-3	Monoamine Oxidase	Metabolic Disease Cardiovascular Disease Inflammation/Immunology
SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.

HY-N0547

Nomilin
Others Metabolic Disease

Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

HY-N0640

Kuromanin chloride Chrysontemin; Cyanidin 3-O-glucoside chloride	Others	Metabolic Disease
Kuromanin (chloride), extracted from mulberry leaves, has been shown to improve blood glucose concentrations and lipid homeostasis and to reduce obesity.

HY-135190

(-)-Cedrene α-cedrene	Bacterial	Cancer Infection Metabolic Disease
(-)-Cedrene (α-cedrene) is a sesquiterpene constituent of cedarwood oils, with anti-leukemic, antimicrobial and anti-obesity activities.

HY-128872

Etrinabdione EHP-101; VCE-004.8	PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB₂ receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity.

HY-147927

Human enteropeptidase-IN-1	Others	Metabolic Disease
Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research.

HY-112489

FSG67
Others Metabolic Disease

FSG67 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor with an IC₅₀ of 24 μM.

HY-12443

PF-5006739	Casein Kinase	Neurological Disease
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner. PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity.

HY-N0114

Evodiamine (+)-Evodiamine; d-Evodiamine	Others	Cancer
Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.

HY-Y0078

Cinnamyl Alcohol
PPAR Metabolic Disease

Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, with anti-obesity activity.

HY-N2268

Gymnemagenin	Antibiotic	Infection Metabolic Disease
Gymnemagenin is a triterpenoid isolated from G. sylvestre. Gymnemagenin is an agent for diabetes and obesity and also possesses antiviral properties.

HY-U00070

Dirlotapide CP742033; Slentrol	Microsomal Triglyceride Transfer Protein (MTP)	Metabolic Disease
Dirlotapide (CP742033) is a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) that reliably produces weight loss in obese dogs.

HY-F0004S

β-Nicotinamide mononucleotide-d4 β-NM-d₄; NMN-d₄	Endogenous Metabolite	Cancer Neurological Disease
β-Nicotinamide mononucleotide-d₄ is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

HY-112920

TM-25659
Others Metabolic Disease

TM-25659 is a transcriptional co-activator with PDZ-binding motif (TAZ) modulator. Anti-osteoporotic and anti-obesity activities.

HY-14472

Tesofensine NS-2330	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.

HY-N5117

Kaempferol 3-sophoroside-7-glucoside	Others	Metabolic Disease
Kaempferol 3-sophoroside-7-glucoside is a bioactive component in roasted Lycium chinense leaves with anti-obesity activity.

HY-B2188

S-Methyl-L-cysteine L-S-Methylcysteine	Reactive Oxygen Species	Metabolic Disease Neurological Disease
S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

HY-N6871

Abietic acid	Bacterial	Cancer Infection Metabolic Disease Inflammation/Immunology
Abietic acid, a diterpene isolated from Colophony, possesses antiproliferative, antibacterial, and anti-obesity properties. Abietic acid inhibits lipoxygenase activity for allergy treatment.

HY-W015464S1

N-Isovaleroylglycine-d2	Endogenous Metabolite	Metabolic Disease
N-Isovaleroylglycine-d₂ is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-W015464S

N-Isovalerylglycine-d9	Endogenous Metabolite	Metabolic Disease
N-Isovalerylglycine-d₉ is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-107542S2

Oleoylethanolamide-d2 N-Oleoylethanolamide-d₂; Oleamide MEA-d₂; Oleic acid monoethanolamide-d₂	Endogenous Metabolite PPAR	Metabolic Disease Cardiovascular Disease
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S

Oleoylethanolamide-d4 N-Oleoylethanolamide-d₄; Oleamide MEA-d₄; Oleic acid monoethanolamide-d₄	Endogenous Metabolite PPAR	Metabolic Disease Cardiovascular Disease
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-147931

Human enteropeptidase-IN-2	Others	Metabolic Disease
Human enteropeptidase-IN-2 (compound 1c) is a highly potent enteropeptidase inhibitor. Human enteropeptidase-IN-2 can be used for anti-obesity research.

HY-U00397

CB1 antagonist 1	Cannabinoid Receptor	Metabolic Disease Inflammation/Immunology Neurological Disease Cardiovascular Disease
CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

HY-N8099

Pulsatilloside C
Others Metabolic Disease

Pulsatilloside C is a compound isolated from Pulsatilla koreana. Pulsatilloside C significantly inhibits adipocyte differentiation.

HY-120851

O-7460	Cannabinoid Receptor	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels.

HY-118930

MK-0493	Melanocortin Receptor	Endocrinology Metabolic Disease
MK-0493 is a potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R), demonstrating significant reductions in energy intake.

HY-147821

CB1-IN-2	Cannabinoid Receptor	Metabolic Disease
CB1-IN-2 (Compound 4g) is a selective CB₁ inhibitor with an IC₅₀ of 0.644 μM. CB1-IN-2 can penetrates BBB and might cause CNS side effect similar with Rimonabant.

HY-15206S

Glyburide-d11	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S1

Glyburide-d3 Glyburide-d₃	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-16278

Pradigastat LCQ-908	Acyltransferase	Metabolic Disease
Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects.

HY-U00396

MC-4R Agonist 1	Melanocortin Receptor	Metabolic Disease Endocrinology
MC-4R Agonist 1 is an agonist of human melanocortin-4 receptor (MC-4R), used in the research of obesity, diabetes, and sexual dysfunction.

HY-138119

γ-Glutamylserine γ-Glu-Ser	Others	Metabolic Disease Neurological Disease
γ-Glutamylserine (γ-Glu-Ser) is a calcium receptor activator. γ-Glutamylserine can be used for Parkinson's disease research, as well as diabetes or obesity study.

HY-101325

BRL 37344 sodium BRL 37344A	Adrenergic Receptor	Metabolic Disease Endocrinology
BRL 37344 sodium (BRL 37344A) is a specific β3-adrenergic receptor agonist. BRL 37344 sodium treatment significantly lowers the body weight of obese mice.

HY-N2673

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Sirtuin	Metabolic Disease Cardiovascular Disease
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via sirtuin3 signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity.

HY-N1411

Platycodin D	AMPK Wnt	Metabolic Disease
Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D.

HY-111317

SIRT1 activator 3	Sirtuin	Metabolic Disease
SIRT1 activator 3 is a potent activator of Sirt1 and suppresses TNF-α in a dose-dependent manner. SIRT1 activator 3 has the potential for anti-obesity or anti-diabetic researches.

HY-N0055

Chlorogenic acid 3-O-Caffeoylquinic acid; Heriguard; NSC-407296	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Bacterial Influenza Virus Endogenous Metabolite	Cancer Infection Inflammation/Immunology
Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb.. It plays several important and therapeutic roles such as antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension.

HY-P4860

Adropin (34-76) (human, mouse, rat)	Akt	Metabolic Disease
Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle. Adropin increases insulin-induced Akt phosphorylation and cell-surface expression of GLUT4, in diet-induced obesity (DIO) mouse.

HY-105008

Secoisolariciresinol diglucoside (S,S)-SDG; (S,S)-LGM2605	Others	Inflammation/Immunology Neurological Disease Cardiovascular Disease
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects.

HY-P3586

HKPao Hunter-killer peptide ao	Apoptosis	Cancer
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles.

HY-N3026

Soyasaponin Ab	PPAR	Metabolic Disease
Soyasaponin Ab is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ).

HY-N3027

Soyasaponin Aa	PPAR	Metabolic Disease
Soyasaponin Aa is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ).

HY-B1779S3

Sucrose-d14 D-(+)-Saccharose-d₁₄	Endogenous Metabolite	Metabolic Disease Cancer
Sucrose-d₁₄ is the deuterium labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preferen

HY-14471

Cetilistat ATL-962	Others	Metabolic Disease
Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC₅₀s of 54.8 nM, and 5.95 nM, respectively.

HY-111588

Xanthoangelol	Apoptosis Monoamine Oxidase Bacterial AMPK	Cancer Infection Inflammation/Immunology
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-136124

Cetilistat impurity 1	Drug Metabolite	Others
Cetilistat impurity 1 is an impurity of Cetilistat. Cetilistat, an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC₅₀s of 54.8 nM, and 5.95 nM, respectively.

HY-15497

AZD7687	Acyltransferase	Metabolic Disease
AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC₅₀ of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research.

HY-W005130

2,4,6-Trihydroxybenzaldehyde	NF-κB	Metabolic Disease
2,4,6-Trihydroxybenzaldehyde is an orally active NF-ĸB inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity.

HY-143312A

V-0219 hydrochloride	GLP Receptor	Metabolic Disease
V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research.

HY-143312

V-0219	GLP Receptor	Metabolic Disease
V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research.

HY-108571

CP-775146	PPAR	Metabolic Disease
CP-775146 is a selective PPARα agonist that binds strongly to the PPARα ligand. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway.

HY-107734

L 152804	Neuropeptide Y Receptor	Metabolic Disease Endocrinology
L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a K_i of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.

HY-14860A

1-Deoxynojirimycin hydrochloride Duvoglustat hydrochloride	Glucosidase PI3K Bacterial Antibiotic	Infection Metabolic Disease
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-14860

1-Deoxynojirimycin Duvoglustat	Glucosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-139077

SCD1 inhibitor-3	Stearoyl-CoA Desaturase (SCD)	Cancer Metabolic Disease
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.

HY-151106

FTO-IN-8	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC₅₀ value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity.

HY-114988

PGE-M tetranor-PGEM	Endogenous Metabolite	Cancer Inflammation/Immunology
PGE-M is a metabolite of prostaglandin E₂ (PEG₂) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer.

HY-19727

FOY 251 free base	Ser/Thr Protease SARS-CoV	Infection Metabolic Disease
FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor. FOY 25 free base inhibits SARS-CoV-2 infection in cells assay.

HY-N7605

11-epi-mogroside V	Others	Metabolic Disease
11-epi-mogroside V is a mogroside in the fruit of Siraitia grosvenori. 11-epi-mogroside V exhibits considerable bioactivity in promoting glucose uptake in human HepG2 cells in vitro.

HY-106425

Omzotirome
TRC-150094
Others Metabolic Disease

Omzotirome (TRC150094), a functional analog of iodothyronines, can be used for the research of hyperlipidaemia (WO2008149379).

HY-148179

Neuropeptide Y5 receptor ligand-1	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y5 receptor ligand-1 (compound 54), a carbazole derivative, is a potent neuropeptide Y5 (NPY-5) receptor antagonist.

HY-124073

Dihydrocapsiate	TRP Channel	Metabolic Disease
Dihydrocapsiate, as a compound of capsinoid family, is an orally active TRPV1 agonist. Dihydrocapsiate can be used for the research of metabolism disease.

HY-138626

ACH-000143	Melatonin Receptor	Metabolic Disease
ACH-000143 is a potent and orally active melatonin receptor agonist, with EC₅₀ values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively.

HY-19727A

FOY 251	Ser/Thr Protease SARS-CoV	Metabolic Disease
FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor. FOY 251 inhibits SARS-CoV-2 infection in cells assay.

HY-N2357

Eudesmin (-)-Eudesmin; Eudesmine; (-)-Eudesmine	Ribosomal S6 Kinase (RSK)	Cancer Infection Metabolic Disease Inflammation/Immunology
Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.

HY-14229

TGR5 Receptor Agonist CCDC	G protein-coupled Bile Acid Receptor 1 Calcium Channel	Metabolic Disease
TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC₅₀s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca²⁺ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity.

HY-17386B

Rosiglitazone potassium BRL 49653 potassium	PPAR TRP Channel Autophagy Apoptosis Ferroptosis	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer.

HY-B1890

(±)-Catechin rel-Cianidanol; rel-Catechuic acid	COX	Cancer Infection Inflammation/Immunology Neurological Disease Cardiovascular Disease
(±)-Catechin (rel-Cianidanol) is the racemate of Catechin. (±)-Catechin has two steric forms of (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 1.4 μM. Anticancer, anti-obesity, antidiabetic, anticardiovascular, anti-infectious, hepatoprotective, and neuroprotective effects.

HY-17386

Rosiglitazone BRL 49653	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.

HY-N2819

Adenanthin	NF-κB	Cancer Inflammation/Immunology
Adenanthin is an inhibitor of thiol-dependent antioxidant enzymes, targeting to Prx 1 and Prx 2. Adenanthin impairs human natural killer (NK) cells effector functions, and killing hepatocellular carcinoma cells. Adenanthin inhibits NF-κB signaling and lipogenesis and the development of obesity by regulating ROS.

HY-N1867

trans-Cinnamyl alcohol	PPAR	Metabolic Disease
trans-Cinnamyl alcohol is a trans-isomer of Cinnamyl alcohol. Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, with anti-obesity activity. trans-Cinnamyl alcohol, belongs to the class of organic compounds known as cinnamyl alcohols, is a primary metabolite.

HY-17386A

Rosiglitazone hydrochloride BRL 49653 hydrochloride	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer.

HY-B1779S5

Sucrose-13C6 D-(+)-Saccharose-¹³C₆	Endogenous Metabolite
Sucrose-¹³C₆ is the ¹³C labeled Sucrose[1]. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al[2].

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a peripherally active, cannabinoid receptor antagonist with limited brain penetration. AM6545 binds to CB1 and CB2 receptors with K_is of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist. AM6545 can be used for the research of obesity and its complications.

HY-19702

PKR activator 3	Pyruvate Kinase	Cancer Metabolic Disease Inflammation/Immunology
PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.

HY-135425

10,12-Tricosadiynoic acid	Acyltransferase	Metabolic Disease
10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism.

HY-N7347

(-)-Hydroxycitric acid lactone Garcinia lactone	ATP Citrate Lyase	Metabolic Disease
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis.

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.

HY-114196

Aclimostat ZGN-1061	Others	Metabolic Disease
Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells.

HY-N5011

5,7-Dimethoxyflavone	Cytochrome P450	Cancer Inflammation/Immunology
5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor.

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Endocrinology Metabolic Disease
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research.

HY-117275S1

Meclofenamic acid-13C6 Meclofenamate-¹³C₆	Isotope-Labeled Compounds Gap Junction Protein Endogenous Metabolite	Inflammation/Immunology
Meclofenamic acid-¹³C₆ is the ¹³C₆ labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.

HY-18260

Bisphenol A	Endogenous Metabolite	Endocrinology
Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.

HY-N7690

3,5,7,3′,4′-Pentamethoxyflavone	Others	Metabolic Disease
3,5,7,3′,4′-Pentamethoxyflavone is a polymethoxyflavonoid that can be extracted from Kaempferia parviflora. 3,5,7,3′,4′-Pentamethoxyflavone can induce adipogenesis on 3T3-L1 preadipocytes by regulating transcription factors at an early stage of differentiation.

HY-120643

BMS-823778 hydrochloride	11β-HSD	Metabolic Disease
BMS-823778 hydrochloride is a potent, selective and orally active 11β-HSD1 inhibitor with an IC₅₀ of 2.3 nM against human 11β-HSD1.

HY-104026B

L-Kynurenine sulfate	Endogenous Metabolite Aryl Hydrocarbon Receptor	Inflammation/Immunology
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.

HY-135280

MRL-650 CB1 inverse agonist 1	Cannabinoid Receptor	Metabolic Disease
MRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC₅₀s of 7.5 nM and 4100 nM for CB1 and CB2 receptors, respectively. Anorexigenic effects.

HY-16007

(-)-Hydroxycitric acid Garcinia acid	ATP Citrate Lyase	Metabolic Disease
(-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss.

HY-12402

SBC-115076	Ser/Thr Protease	Cardiovascular Disease
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.

HY-B1320

Meclofenamic acid sodium Meclofenamate sodium	Gap Junction Protein Endogenous Metabolite	Inflammation/Immunology
Meclofenamic acid (Meclofenamate) sodium is a nonsteroidal anti-inflammatory agent (NSAID) approved for use in arthritis (osteo and rheumatoid), analgesia (mild to moderate pain), dysmenorrhea, and heavy menstrual blood loss (menorrhagia). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of *fat mass and obesity-associated (FTO)* enzyme inhibitor.

HY-130208

Thiodigalactoside TDG	Galectin	Cancer Metabolic Disease Inflammation/Immunology
Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with K_d values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.

HY-103479

GOAT-IN-1	Acyltransferase	Cancer Metabolic Disease Neurological Disease Cardiovascular Disease
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-P3584

(Pro3) GIP, human (Pro3) Gastric Inhibitory Peptide, human	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with K_i/ K_d values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.

HY-117275S

Meclofenamic acid-d4 Meclofenamate-d₄	Gap Junction Protein Endogenous Metabolite	Inflammation/Immunology
Meclofenamic acid-d₄ is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker[1][2][3].

HY-124822

COH-SR4	AMPK	Cancer Metabolic Disease
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a recombinant human GLP-1 (rhGLP-1) polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).

HY-117769

GSK837149A	Fatty Acid Synthase (FASN)	Metabolic Disease
GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (K_i=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.

HY-N5097

13-Oxo-9E,11E-octadecadienoic acid	PPAR	Metabolic Disease
13-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent PPARα activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic triglyceride in obese diabetic mice.

HY-N0828

Pterostilbene	Autophagy	Cancer Inflammation/Immunology
Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties. Pterostilbene blocks ROS production, also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide.

HY-18260S1

Bisphenol A-d6	Endogenous Metabolite	Endocrinology
Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].

HY-P2812

Phospholipase D PLD	Phospholipase	Cancer Endocrinology Inflammation/Immunology Neurological Disease
Phospholipase D (PLD) is an enzyme of the phospholipase superfamily, which widely exists in bacteria, yeast, plants, animals and viruses, and is often used in biochemical research. Phospholipase D can catalyze the hydrolysis of phosphodiester bonds in glycerophospholipids to produce phosphatidic acid and soluble choline. Phospholipase D is involved in a variety of disease-related processes, including diabetes, atherogenesis, obesity, tumorigenesis, immune response, and neuroendocrine function.

HY-107623

TC-MCH 7c	MCHR1 (GPR24)	Metabolic Disease
TC-MCH 7c, a phenylpyridone derivative, is an orally available, selective and brain-penetrable MCH₁R antagonist with an IC₅₀ of 5.6 nM for hMCH₁R. TC-MCH 7c has K_is of 3.4 nM and 3.0 nM of human and mouse MCH₁R, respectively.

HY-150976

β-Glucuronidase/hCAII-IN-1	Carbonic Anhydrase	Cancer Metabolic Disease Neurological Disease
β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC₅₀ of 440.1 μM and 4.91 μM, respectively.

HY-124489

2-Hydroxyestradiol	Endogenous Metabolite	Metabolic Disease
2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity.

HY-150973

hCAII-IN-4	Carbonic Anhydrase	Cancer Metabolic Disease Neurological Disease
hCAII-IN-4 (Compound 12j) is a potent hCA II inhibitor with an IC₅₀ of 7.78 μM. hCAII-IN-4 also inhibits β-glucuronidase with an IC₅₀ of 773.9 μM.

HY-147626

GLP-1R agonist 13
GLP Receptor Metabolic Disease

GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist.

HY-18260S

Bisphenol A-d16	Endogenous Metabolite	Endocrinology
Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-N4103

Fucosterol	PARP Endogenous Metabolite	Cancer Metabolic Disease
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities. Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research.

HY-18260S4

Bisphenol A-d4	Endogenous Metabolite	Endocrinology
Bisphenol A-d₄ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S5

Bisphenol A-d4-1	Endogenous Metabolite	Endocrinology
Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-117843

Ppc-1	Mitochondrial Metabolism Interleukin Related Bacterial	Infection Metabolic Disease Inflammation/Immunology
Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen *Porphyromonas gingivalis. Ppc-1 has anti-obesity*, antibacterial and anti-inflammatory activities.

HY-120327

KY-226	Phosphatase	Metabolic Disease Neurological Disease
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury.

HY-18260S3

Bisphenol A-4d	Endogenous Metabolite	Endocrinology
Bisphenol A-d₈ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].

HY-W011220

Ciglitazone ADD-3878; U-63287	PPAR	Cancer Cardiovascular Disease
Ciglitazone is a potent and selective PPARγ agonist (EC₅₀=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells.

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes.

HY-101986A

BIIE-0246 hydrochloride AR-H 053591 hydrochloride	Neuropeptide Y Receptor	Metabolic Disease
BIIE-0246 hydrochloride (AR-H 053591 hydrochloride) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC₅₀ value of 15 nM for rat [¹²⁵I]PYY_3-36. BIIE-0246 hydrochloride decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 hydrochloride reduces albuminuria in ADR nephropathy.

HY-150701

INCB13739	Glucocorticoid Receptor Mineralocorticoid Receptor 11β-HSD	Metabolic Disease
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC₅₀ values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research.

HY-116771A

CL 316243	Adrenergic Receptor	Metabolic Disease
CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC₅₀ of 3 nM, but is an extremely poor to β1/2- receptors.CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence.

HY-N6769

Radicicol Monorden	HSP Bacterial Antibiotic Parasite	Infection
Radicicol is an inhibitor of Hsp90 with an IC₅₀ value < 1 μM, and leads to proteasomal degradation. Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB. Radicicol is also an inhibitor of *fat mass and obesity-associated protein* (FTO), with an IC₅₀ value of 16.04 μM.

HY-N0055S

Chlorogenic acid-13C3 3-O-Caffeoylquinic acid-₁₃C³; Heriguard-₁₃C³; NSC-407296-₁₃C³	Isotope-Labeled Compounds	Cancer
Chlorogenic acid-¹³C₃ (Heriguard-¹³C₃; NSC-407296-¹³C₃) is ¹³C- and ¹⁵N-labeled Chlorogenic acid (HY-N0055). Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb.. It plays several important and therapeutic roles such as antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension.

HY-117275

Meclofenamic acid Meclofenamate	Fat Mass and Obesity-associated Protein (FTO) Potassium Channel Gap Junction Protein Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Neurological Disease
Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC₅₀ values of 56.0 and 155.9 μM, respectively.

HY-117275A

Meclofenamic acid sodium hydrate Meclofenamate sodium hydrate	Fat Mass and Obesity-associated Protein (FTO) Potassium Channel Gap Junction Protein Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Neurological Disease
Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC₅₀ values of 56.0 and 155.9 μM, respectively.

HY-103138

(Rac)-WAY-161503 hydrochloride	5-HT Receptor	Metabolic Disease Neurological Disease
(Rac)-WAY-161503 hydrochloride is a potent, selective, high affinity 5-HT_2C receptor agonist with a K_i of 4 nM and an EC₅₀ of 12 nM. (Rac)-WAY-161503 hydrochloride displays higher affinity for 5-HT_2C than 5-HT_2A and 5-HT_2B receptors. (Rac)-WAY-161503 hydrochloride has anti-obesity and antidepressant effects.

HY-103138A

(Rac)-WAY-161503	5-HT Receptor	Metabolic Disease Neurological Disease
(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT_2C receptor agonist with a K_i of 4 nM and an EC₅₀ of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT_2C than 5-HT_2A and 5-HT_2B receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects.

HY-123986

CTPI-2	Mitochondrial Metabolism	Cancer Inflammation/Immunology
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a K_D of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity.

HY-P1723A

Spexin TFA Neuropeptide Q TFA	Neuropeptide Y Receptor
Spexin TFA is a potent galanin receptor 2/3 (GAL2/GAL3) agonist (EC₅₀ values are 45.7 and 112.2 nM, respectively). Spexin TFA exhibits no significant activity at galanin receptor 1. Spexin TFA is an endogenous satiety-inducing peptide; Spexin TFA inhibits long chain fatty acid uptake by adipocytes and decreases food consumption in diet-induced obese mice and rats. Spexin TFA attenuates LH secretion in goldfish. Spexin TFA exhibits anxiolytic effects in vivo.

HY-19762

GSK1940029 SCD inhibitor 1	Stearoyl-CoA Desaturase (SCD)	Cancer
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Cancer Metabolic Disease
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells.

HY-117549

Ibrolipim NO-1886	Others	Cardiovascular Disease
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects.

HY-129658

TT-OAD2 free base	GCGR	Metabolic Disease
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.

HY-N8518

Malabaricone C
Others Metabolic Disease

Malabaricone C is a natural sphingomyelin synthase (SMS) inhibitor with IC₅₀s of 3 and 1.5 μM for SMS 1 and 2, respectively.
HY-129658A

TT-OAD2
GCGR Metabolic Disease

TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 has the potential for diabetes treatment.

HY-14393

Emodin Frangula emodin	SARS-CoV Casein Kinase Autophagy 11β-HSD	Cancer
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects. Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice.

HY-N4226

1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid	AP-1	Inflammation/Immunology Cancer
1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid is from Cordyceps bassiana, which is one of Cordyceps species with anti-oxidative, anti-cancer, anti-inflammatory, anti-diabetic, anti-obesity, anti-angiogenic, and anti-nociceptive activities. 1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid targets to block AP-1-mediated luciferase activity, implying it has an anti-inflammatory function.

HY-N11507

Tibesaikosaponin V TKV	PPAR	Metabolic Disease
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders.

HY-117427

D5D-IN-326	Others	Metabolic Disease
D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC₅₀s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice.

HY-122591

PTUPB
COX Cancer Metabolic Disease

PTUPB is a potent and dual sEH and COX-2 enzymes inhibitor with IC₅₀ of 0.9 nM and 1.26 μM, respectively.
HY-147956

hCA VB-IN-1
Carbonic Anhydrase Metabolic Disease Neurological Disease

hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a K_I of 515.7 nM.

HY-103171

BAY 60-6583	Adenosine Receptor	Inflammation/Immunology Cardiovascular Disease
BAY 60-6583 is a potent and high-affinity agonist of adenosine A_2B receptor (EC₅₀ = 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with K_i values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model.

HY-147234

Sirtuin modulator 2	Sirtuin	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease Cardiovascular Disease
Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED₅₀ equal or less than 50 μM.

HY-121744

PS10	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM). PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy.PDK: pyruvate dehydrogenase kinase

HY-14393S

Emodin-d4 Frangula emodin-d₄	Isotope-Labeled Compounds SARS-CoV Casein Kinase Autophagy 11β-HSD	Cancer
Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

HY-13524

AG-1478 Tyrphostin AG-1478; NSC 693255	EGFR HCV Influenza Virus	Cancer Infection Metabolic Disease Cardiovascular Disease
AG-1478 (Tyrphostin AG-1478) is a selective EGFR tyrosine kinase inhibitor with IC₅₀ of 3 nM. AG-1478 has antiviral effects against HCV and encephalomyocarditis virus (EMCV).

HY-124314

LEI-106	MAGL	Metabolic Disease
LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor with an IC₅₀ of 18 nM for DAGL-α and a K_i of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [¹⁴C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a K_i of 0.7 μM.

HY-N6626

Pyraclostrobin	Fungal Bacterial	Infection Metabolic Disease
Pyraclostrobin is a strobilurin fungicide that inhibits mitochondrial complex III of fungal and mammalian cells. Pyraclostrobin induces triglyceride accumulation and triglyceride accumulation in 3T3-L1 cells.

HY-13524A

AG-1478 hydrochloride Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride	EGFR HCV Influenza Virus	Cancer Infection Metabolic Disease Cardiovascular Disease
AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective EGFR tyrosine kinase inhibitor with IC₅₀ of 3 nM. AG-1478 hydrochloride has antiviral effects against HCV and encephalomyocarditis virus (EMCV).

HY-100277

Mifobate SR-202	PPAR	Metabolic Disease
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC₅₀=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects.

HY-110353

CU-T12-9	Toll-like Receptor (TLR)	Cancer Inflammation/Immunology
CU-T12-9 is a specific TLR1/2 agonist with EC₅₀ of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.

HY-Y1750A

β-Aminopropionitrile hydrochloride BAPN hydrochloride	Monoamine Oxidase Endogenous Metabolite	Cancer Metabolic Disease
β-Aminopropionitrile (BAPN) hydrochloride is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile hydrochloride targets the active site of LOX or LOXL isoenzymes.

HY-Y1750

β-Aminopropionitrile BAPN	Monoamine Oxidase Endogenous Metabolite	Cancer Metabolic Disease
β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes.

HY-13012G

RepSox E-616452; SJN 2511	TGF-β Receptor	Metabolic Disease
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor.

HY-147622

GLP-1R agonist 9	GCGR	Metabolic Disease
GLP-1R agonist 9 (Compound 96) is a GLP-1R agonist with EC₅₀ values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively.

HY-124187

Pinolenic acid ethyl ester Ethyl pinolenate	Biochemical Assay Reagents	Others
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

HY-Q49697

Sirtuin modulator 3
Sirtuin Cancer Metabolic Disease Inflammation/Immunology

Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a sirtuin modulator.

HY-W082785A

L6H21	TNF Receptor Interleukin Related Toll-like Receptor (TLR) NF-κB NOD-like Receptor (NLR) Apoptosis Caspase Bcl-2 Family Reactive Oxygen Species	Metabolic Disease Inflammation/Immunology Neurological Disease
L6H21, a Chalcone (HY-121054) derivative, is an orally active, potent and specific myeloid differentiation 2 (MD-2) inhibitor. L6H21 directly binds to MD-2 protein with a high affinity and low K_D value of 33.3 μM, blocking the formation of the LPS-TLR4/MD-2 complex. L6H21 inhibits LPS-induced expression of TNF-α and IL-6 in RAW264.7 macrophages, with IC₅₀ values of 6.58 and 8.59 μM, respectively. L6H21 can be used for alcoholic liver disease, metabolic disturbance and neuroinflammation research.

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Cancer Infection Metabolic Disease
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.

HY-A0068

Aurothioglucose Gold thioglucose	NF-κB HIV Reactive Oxygen Species	Cancer Infection Inflammation/Immunology
Aurothioglucose (Gold thioglucose), containing monovalent gold ion, is a potent active-site inhibitor of TrxR1 (thioredoxin reductase 1), with an IC₅₀ of 65 nM. Aurothioglucose inhibits the DNA binding of NF-κB in vitro. Aurothioglucose shows anti-HIV and anti-rheumatic activities.

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library

2024 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2024 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L091

Lipid Metabolism Compound Library

553 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 553 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

HY-L078

Gut Microbial Metabolite Library

222 compounds

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 222 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

HY-L123

Human Metabolite Library

4996 compounds

Human metabolism is an integral part of cellular function that reflects individual differences in health, disease, diet, and lifestyle. Many health conditions such as obesity, diabetes, hypertension, heart disease, and cancer are associated with abnormal metabolic states. In the pathological state of the human body, metabolic pathways are significantly altered, resulting in aberrant levels of intermediates or end-products that can be viewed as potential diagnostic biomarkers or even therapeutic targets. Therefore, detection, identification and quantification of human metabolites are very important for drug metabolism research in drug development.

MCE offers a unique collection of 4996 human metabolites, including endogenous metabolites and exogenous metabolites, covering multiple structure types, such as lipids, amino acids, nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins,. MCE Human Metabolites Library is a helpful tool for studying the relationship between diseases and metabolism.

HY-L103

Anti-Colorectal Cancer Compound Library

1426 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1426 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-137840

Hippuryl-L-phenylalanine	Biochemical Assay Reagents
Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity.

HY-P1775

Carbonic anhydrase EC 4.2.1.1	Enzyme
Carbonic anhydrase is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy.

HY-P2812

Phospholipase D

PLD

Enzyme

Phospholipase D (PLD) is an enzyme of the phospholipase superfamily, which widely exists in bacteria, yeast, plants, animals and viruses, and is often used in biochemical research. Phospholipase D can catalyze the hydrolysis of phosphodiester bonds in glycerophospholipids to produce phosphatidic acid and soluble choline. Phospholipase D is involved in a variety of disease-related processes, including diabetes, atherogenesis, obesity, tumorigenesis, immune response, and neuroendocrine function.

HY-124187

Pinolenic acid ethyl ester

Ethyl pinolenate

Biochemical Assay Reagents

Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

Cat. No.	Product Name	Target	Research Area

HY-P3462

Cagrilintide	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

HY-P1432

K-(D-1-Nal)-FwLL-NH2	GHSR	Metabolic Disease
K-(D-1-Nal)-FwLL-NH2 is a high affinity, potent and inverse ghrelin receptor agonist (EC₅₀=3.4 nM, K_i=4.9 nM). K-(D-1-Nal)-FwLL-NH2 can be used for the research of obesity.

HY-P3495

Pegapamodutide
LY-2944876
GLP Receptor Metabolic Disease

Pegapamodutide (LY-2944876) is a glucagon-GLP-1 receptor agonist, and can be used in type 2 diabetes and obesity research.

HY-P1230

HAEGT	Dipeptidyl Peptidase GLP Receptor	Metabolic Disease
HAEGT is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity.

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies.

HY-P3848

Tyr0-Neurokinin A	Peptides	Metabolic Disease Neurological Disease
Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes.

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Endocrinology Metabolic Disease
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.

HY-P3677

Neuropeptide Y (2-36) (porcine)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y (2-36) (porcine) is a porcine-derived neuropeptide with 97.14% homology to rat/human origin. Neuropeptide Y (2-36) (porcine) is also a rat neuropeptide receptor agonist, with EC₅₀ values of 1.2, 1.6 and 3.4 nM for receptor of Y5, Y2 and Y1 respectively. Neuropeptide Y (2-36) (porcine) can be used in studies related to obesity and eating disorders.

HY-P3506

Retatrutide LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits for human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.

HY-145632

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.

HY-P3506A

Retatrutide TFA LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA inhibits for human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.

HY-P2048A

MOTS-c(human) acetate	AMPK GLUT	Metabolic Disease
MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity.

HY-P2231

Cotadutide MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).

HY-P2231A

Cotadutide acetate MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D).

HY-P4815

Prokineticin 2 Isoform 2 (human)	Endogenous Metabolite	Metabolic Disease Neurological Disease
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity.

HY-P3866

[Asu1,6]-Oxytocin	Peptides	Metabolic Disease
[Asu1,6]-Oxytocin is an analog of oxytocin. [Asu1,6]-Oxytocin reverses insulin resistance and glucose intolerance prior to reduction of obesity. [Asu1,6]-Oxytocin has the potential for the research of obesity and diabetes.

HY-P1910

BDC2.5 mimotope 1040-51
Peptides Metabolic Disease

BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice.

HY-P3341

OB3	Peptides	Cancer Metabolic Disease Inflammation/Immunology
OB3, a derivative of Leptin, show more effective than leptin in reducing obesity and diabetes in mouse models. OB3 can reduce Leptin-related inflammation and proliferation in hepatocellular carcinoma cells.

HY-P4860

Adropin (34-76) (human, mouse, rat)	Akt	Metabolic Disease
Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle. Adropin increases insulin-induced Akt phosphorylation and cell-surface expression of GLUT4, in diet-induced obesity (DIO) mouse.

HY-P3586

HKPao Hunter-killer peptide ao	Apoptosis	Cancer
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles.

HY-P4657

Human Growth Hormone (1-43)	Peptides	Endocrinology
Human Growth Hormone (1-43) is an N-terminal fragment of human growth hormone with specific and pronounced insulin-like activity. Human Growth Hormone (1-43) can be used to study the function and metabolic pathways of growth hormone, a potential obesity-related factor.

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.

HY-P3584

(Pro3) GIP, human (Pro3) Gastric Inhibitory Peptide, human	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with K_i/ K_d values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a recombinant human GLP-1 (rhGLP-1) polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).

HY-P3568

Adipokinetic hormone (Gryllus bimaculatus) Grybi-AKH	Peptides	Metabolic Disease
Adipokinetic hormone Gryllus bimaculatus (Grybi-AKH) is an adipokinetic hormone that regulates energy homeostasis in insects by mobilizing lipid and carbohydrate from the fat body. Adipokinetic hormone Gryllus bimaculatus stimulates the locomotor activity of the two-spotted cricket. Adipokinetic hormone Gryllus bimaculatus can also be used in studies to regulate body weight, induce weight loss and alleviate glycogen storage disorders in humans.

HY-P1238A

Neuromedin U, rat TFA Neuromedin U (rat) (TFA); Rat neuromedin U-23 TFA	Peptides	Neurological Disease
Neuromedin U, rat TFA is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.

HY-P1238

Neuromedin U, rat Neuromedin U (rat); Rat neuromedin U-23	Peptides	Neurological Disease
Neuromedin U, rat is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes.

HY-P2472

Orphan GPCR SP9155 agonist P550 (mouse, rat) 26RFa (mouse, rat)	Peptides	Metabolic Disease
Orphan GPCR SP9155 agonist P550 (mouse, rat) (26RFa (mouse, rat)), a member of the RFamide peptide family with orexigenic effect, is the cognate ligand of the mouse orphan receptor GPR103, also designated SP9155 or AQ27.

HY-P1723A

Spexin TFA Neuropeptide Q TFA	Neuropeptide Y Receptor
Spexin TFA is a potent galanin receptor 2/3 (GAL2/GAL3) agonist (EC₅₀ values are 45.7 and 112.2 nM, respectively). Spexin TFA exhibits no significant activity at galanin receptor 1. Spexin TFA is an endogenous satiety-inducing peptide; Spexin TFA inhibits long chain fatty acid uptake by adipocytes and decreases food consumption in diet-induced obese mice and rats. Spexin TFA attenuates LH secretion in goldfish. Spexin TFA exhibits anxiolytic effects in vivo.

Cat. No.	Product Name	Target	Category

HY-N0200

Albaspidin AP	Fatty Acid Synthase (FASN)	Structural Classification Natural Products Plants Source classification Dryopteris crassirhizoma Nakai Dryopteridaceae Metabolic Disease Disease Research Fields Classification of Application Fields
Albaspidin AP inhibits fatty acid synthase (FAS) with an IC₅₀ value of 71.7 μM. Fatty acid synthase (FAS) is emerging as a potential therapeutic target for cancer and obesity.

HY-N10606

Uvagrandol	Glucosidase	Natural Products Plants Annonaceae Uvaria grandiflora Roxb.
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC₅₀: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity.

HY-N10428

Ganoapplanoid F	Others	Terpenoids Source classification Plants Polyporaceae
Ganoapplanoid F, a highly oxygenated lanostane triterpenoid from Ganoderma applanatum, inhibits lipid accumulation in adipocytes. Ganoapplanoid F can be used for the research of obesity.

HY-N7653

Azaleatin	Dipeptidyl Peptidase	Flavonoids Flavonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Compositae Carthamus tinctorius L.
Azaleatin is an O-methylated flavonol isolated from Rhododendron species. Azaleatin is a dipeptidyl peptidase-IV inhibitor. Azaleatin can be used for the research of type-2 diabetes and obesity.

HY-150012

N-Lactoyl-Phenylalanine	Endogenous Metabolite	Structural Classification Ketones, Aldehydes, Acids
N-Lactoyl-Phenylalanine is a blood-borne signalling metabolite and can be used for obesity research. N-Lactoyl-Phenylalanine is exercise-inducible.

HY-F0004

β-Nicotinamide mononucleotide β-NM; NMN	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Neurological Disease Anti-aging Source classification Endogenous metabolite Disease markers Other disease
β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD⁺ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity.

HY-113334

Turanose	Endogenous Metabolite	Saccharides Structural Classification Endogenous metabolite Animals Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research.

HY-139058

23-epi-26-Deoxyactein 27-Deoxyactein	PPAR	Triterpenes Terpenoids Structural Classification other families Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

HY-N2925

β-Amyrone β-Amyron	Fungal COX PPAR	Triterpenes Structural Classification Sambucus adnata Wall. ex DC. Caprifoliaceae Plants Source classification
β-Amyrone (β-Amyron) is a triterpene compound which has anti-inflammatory activity through inhibiting the expression of COX-2. β-Amyrone has antifungal activity , as well as antiviral activity against Chikungunya virus. β-Amyrone also inhibits α-glucosidase and acetylcholinesterase (AChE) activity. β-Amyrone can be used in the research of disease like inflammation, infection, and obesity.

HY-N7687

Caulophyllogenin	PPAR	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Leguminosae Acacia catechu (Linn. f.) Willd.
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation.

HY-B1779

Sucrose D-(+)-Saccharose	Endogenous Metabolite	Saccharides Polysaccharides Biological Pesticide Research Metabolic Disease Disease Research Fields Agricultural Research Classification of Application Fields Source classification Plants other families Endogenous metabolite
Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al.

HY-N3127

Orobol	Casein Kinase PI3K VEGFR	Flavonoids Isoflavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Leguminosae Glycine max (L.) merr
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ).

HY-W015464

N-Isovaleroylglycine	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Endocrine diseases Nervous System Disorder
N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-107542

Oleoylethanolamide N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Endogenous Metabolite PPAR	Natural Products Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Endogenous metabolite
Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N2302

Fucoxanthin all-trans-Fucoxanthin	Others	Natural Products Inflammation/Immunology Metabolic Disease Disease Research Fields Cancer Anti-aging Classification of Application Fields Source classification Plants other families Marine natural products Marine algae
Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

HY-N4042

Hirsutenone	PI3K ERK	Phenols Polyphenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Betulaceae Alnus cremastogyne Burk.
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity.

HY-N0547

Nomilin	Others	Triterpenes Terpenoids Structural Classification Rutaceae Plants Source classification Citrus Metabolic Disease Disease Research Fields Classification of Application Fields
Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

HY-N0640

Kuromanin chloride Chrysontemin; Cyanidin 3-O-glucoside chloride	Others	Flavonoids Anthocyans Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Moraceae Morus alba Linn.
Kuromanin (chloride), extracted from mulberry leaves, has been shown to improve blood glucose concentrations and lipid homeostasis and to reduce obesity.

HY-135190

(-)-Cedrene α-cedrene	Bacterial	Sesquiterpenes Terpenoids Structural Classification Pinaceae Cedrus deodara (Roxburgh) G. Don Plants Source classification Infection Metabolic Disease Disease Research Fields Classification of Application Fields
(-)-Cedrene (α-cedrene) is a sesquiterpene constituent of cedarwood oils, with anti-leukemic, antimicrobial and anti-obesity activities.

HY-N0114

Evodiamine (+)-Evodiamine; d-Evodiamine	Others	Alkaloids Piperidine Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Rutaceae Evodia rutaecarpa (Juss.) Benth.
Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.

HY-Y0078

Cinnamyl Alcohol	PPAR	Phenylpropanoids Simple Phenylpropanols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Fagaceae Castanea mollissima Bl.
Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, with anti-obesity activity.

HY-N2268

Gymnemagenin	Antibiotic	Triterpenes Terpenoids Structural Classification Asclepiadaceae Gymnema sylvestre (Retz.) Schult. Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Gymnemagenin is a triterpenoid isolated from G. sylvestre. Gymnemagenin is an agent for diabetes and obesity and also possesses antiviral properties.

HY-N5117

Kaempferol 3-sophoroside-7-glucoside	Others	Flavonoids Flavonols Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Euphorbiaceae Sauropus spatulifolius Beille
Kaempferol 3-sophoroside-7-glucoside is a bioactive component in roasted Lycium chinense leaves with anti-obesity activity.

HY-B2188

S-Methyl-L-cysteine L-S-Methylcysteine	Reactive Oxygen Species	Ketones, Aldehydes, Acids Source classification Plants other families
S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

HY-N6871

Abietic acid	Bacterial	Structural Classification Ketones, Aldehydes, Acids Pinaceae Colophony Plants Inflammation/Immunology Infection Metabolic Disease Disease Research Fields Classification of Application Fields
Abietic acid, a diterpene isolated from Colophony, possesses antiproliferative, antibacterial, and anti-obesity properties. Abietic acid inhibits lipoxygenase activity for allergy treatment.

HY-N8099

Pulsatilloside C	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Ranunculaceae Pulsatilla cernua (Thunb.) Bercht. et Opiz.
Pulsatilloside C is a compound isolated from Pulsatilla koreana. Pulsatilloside C significantly inhibits adipocyte differentiation.

HY-N2673

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Sirtuin	Structural Classification Phenols Polyphenols Gramineae Secale cereale Plants Source classification
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via sirtuin3 signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity.

HY-N1411

Platycodin D	AMPK Wnt	Triterpenes Terpenoids Structural Classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D.

HY-N0055

Chlorogenic acid 3-O-Caffeoylquinic acid; Heriguard; NSC-407296	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Bacterial Influenza Virus Endogenous Metabolite	Phenylpropanoids Phenols Polyphenols Structural Classification Simple Phenylpropanols Caprifoliaceae Endogenous metabolite Lonicera japonica Thunb. Plants Source classification Inflammation/Immunology Infection Disease Research Fields Cancer Anti-aging Classification of Application Fields
Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb.. It plays several important and therapeutic roles such as antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension.

HY-105008

Secoisolariciresinol diglucoside (S,S)-SDG; (S,S)-LGM2605	Others	Phenylpropanoids Lignans Phenols Polyphenols Classification of Application Fields Disease Research Fields Cardiovascular Disease Neurological Disease Source classification Plants Linaceae Linum usitatissimum Linn.
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects.

HY-N3026

Soyasaponin Ab	PPAR	Triterpenes Terpenoids Structural Classification Leguminosae Plants Source classification Glycine max (L.) merr Metabolic Disease Disease Research Fields Classification of Application Fields
Soyasaponin Ab is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ).

HY-N3027

Soyasaponin Aa	PPAR	Triterpenes Terpenoids Structural Classification Leguminosae Plants Source classification Glycine max (L.) merr Metabolic Disease Disease Research Fields Classification of Application Fields
Soyasaponin Aa is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ).

HY-111588

Xanthoangelol	Apoptosis Monoamine Oxidase Bacterial AMPK	Chalcones Phenols Polyphenols Structural Classification Flavonoids Umbelliferae Angelica keiskei Plants Source classification Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-W005130

2,4,6-Trihydroxybenzaldehyde	NF-κB	Monophenols Phenols Animals
2,4,6-Trihydroxybenzaldehyde is an orally active NF-ĸB inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity.

HY-14860A

1-Deoxynojirimycin hydrochloride Duvoglustat hydrochloride	Glucosidase PI3K Bacterial Antibiotic	Saccharides Monosaccharides Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Commelinaceae Commelina communis
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-14860

1-Deoxynojirimycin Duvoglustat	Glucosidase PI3K	Alkaloids Piperidine Alkaloids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Moraceae Morus alba Linn.
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features.

HY-N7605

11-epi-mogroside V	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Cucurbitaceae Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang
11-epi-mogroside V is a mogroside in the fruit of Siraitia grosvenori. 11-epi-mogroside V exhibits considerable bioactivity in promoting glucose uptake in human HepG2 cells in vitro.

HY-124073

Dihydrocapsiate	TRP Channel	Structural Classification Monophenols Phenols Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Solanaceae Capsicum annuum L.
Dihydrocapsiate, as a compound of capsinoid family, is an orally active TRPV1 agonist. Dihydrocapsiate can be used for the research of metabolism disease.

HY-N2357

Eudesmin (-)-Eudesmin; Eudesmine; (-)-Eudesmine	Ribosomal S6 Kinase (RSK)	Phenylpropanoids Lignans Classification of Application Fields Disease Research Fields Infection Inflammation/Immunology Metabolic Disease Source classification Plants Magnoliaceae Magnolia Liliflora Desr.
Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.

HY-B1890

(±)-Catechin rel-Cianidanol; rel-Catechuic acid	COX	Phenols Polyphenols Classification of Application Fields Disease Research Fields Cardiovascular Disease Infection Inflammation/Immunology Neurological Disease Source classification Plants Theaceae Camellia sinensis (L.) O. Ktze.
(±)-Catechin (rel-Cianidanol) is the racemate of Catechin. (±)-Catechin has two steric forms of (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 1.4 μM. Anticancer, anti-obesity, antidiabetic, anticardiovascular, anti-infectious, hepatoprotective, and neuroprotective effects.

HY-N2819

Adenanthin	NF-κB	Structural Classification Terpenoids Diterpenoids Labiatae Isodon adenanthus (Diels) Kudo Plants Source classification
Adenanthin is an inhibitor of thiol-dependent antioxidant enzymes, targeting to Prx 1 and Prx 2. Adenanthin impairs human natural killer (NK) cells effector functions, and killing hepatocellular carcinoma cells. Adenanthin inhibits NF-κB signaling and lipogenesis and the development of obesity by regulating ROS.

HY-N1867

trans-Cinnamyl alcohol	PPAR	Natural Products Source classification Plants Rosaceae
trans-Cinnamyl alcohol is a trans-isomer of Cinnamyl alcohol. Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, with anti-obesity activity. trans-Cinnamyl alcohol, belongs to the class of organic compounds known as cinnamyl alcohols, is a primary metabolite.

HY-N7347

(-)-Hydroxycitric acid lactone Garcinia lactone	ATP Citrate Lyase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis.

HY-N5011

5,7-Dimethoxyflavone	Cytochrome P450	Flavones Flavonoids Inflammation/Immunology Disease Research Fields Cancer Classification of Application Fields Plants Zingiberaceae Kaempferia parviflora
5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor.

HY-18260

Bisphenol A	Endogenous Metabolite	Phenols Polyphenols Classification of Application Fields Disease Research Fields Endocrinology Source classification Endogenous metabolite
Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.

HY-N7690

3,5,7,3′,4′-Pentamethoxyflavone	Others	Structural Classification Flavones Flavonoids Plants Zingiberaceae Metabolic Disease Disease Research Fields Classification of Application Fields
3,5,7,3′,4′-Pentamethoxyflavone is a polymethoxyflavonoid that can be extracted from Kaempferia parviflora. 3,5,7,3′,4′-Pentamethoxyflavone can induce adipogenesis on 3T3-L1 preadipocytes by regulating transcription factors at an early stage of differentiation.

HY-104026B

L-Kynurenine sulfate	Endogenous Metabolite Aryl Hydrocarbon Receptor	Classification of Application Fields Disease Research Fields Inflammation/Immunology
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.

HY-16007

(-)-Hydroxycitric acid Garcinia acid	ATP Citrate Lyase	Ketones, Aldehydes, Acids Metabolic Disease Disease Research Fields Classification of Application Fields Source classification Plants Guttiferae Garcinia cambogia
(-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss.

HY-N5097

13-Oxo-9E,11E-octadecadienoic acid	PPAR	Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
13-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent PPARα activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic triglyceride in obese diabetic mice.

HY-N0828

Pterostilbene	Autophagy	Monophenols Phenols Stilbenes Structural Classification other families Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties. Pterostilbene blocks ROS production, also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide.

HY-N4103

Fucosterol	PARP Endogenous Metabolite	Steroids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families Endogenous metabolite
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities. Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research.

HY-N6769

Radicicol Monorden	HSP Bacterial Antibiotic Parasite	Antibiotics Phenols Polyphenols Structural Classification Macrolide Antibiotics Marine microorganism Microorganisms Marine natural products Source classification Infection Disease Research Fields Classification of Application Fields
Radicicol is an inhibitor of Hsp90 with an IC₅₀ value < 1 μM, and leads to proteasomal degradation. Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB. Radicicol is also an inhibitor of *fat mass and obesity-associated protein* (FTO), with an IC₅₀ value of 16.04 μM.

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Indole Alkaloids Alkaloids Structural Classification other families Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells.

HY-N8518

Malabaricone C	Others	Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Myristicaceae Myristica fragrans Houtt.
Malabaricone C is a natural sphingomyelin synthase (SMS) inhibitor with IC₅₀s of 3 and 1.5 μM for SMS 1 and 2, respectively.

HY-14393

Emodin Frangula emodin	SARS-CoV Casein Kinase Autophagy 11β-HSD	Quinones Anthraquinones Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Polygonaceae Rheum palmatum L.
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects. Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice.

HY-N4226

1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid	AP-1	Ketones, Aldehydes, Acids Disease Research Fields Cancer Classification of Application Fields Source classification Plants other families Microorganisms
1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid is from Cordyceps bassiana, which is one of Cordyceps species with anti-oxidative, anti-cancer, anti-inflammatory, anti-diabetic, anti-obesity, anti-angiogenic, and anti-nociceptive activities. 1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid targets to block AP-1-mediated luciferase activity, implying it has an anti-inflammatory function.

HY-N11507

Tibesaikosaponin V TKV	PPAR	Triterpenes Structural Classification Terpenoids Umbelliferae Plants Source classification
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders.

HY-Y1750

β-Aminopropionitrile BAPN	Monoamine Oxidase Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Cancer Source classification Endogenous metabolite
β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes.

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Structural Classification Phenols Polyphenols Rosaceae Plants Agrimonia pilosa Ledeb. Metabolic Disease Disease Research Fields Classification of Application Fields
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.

Species:	Human (4) Rat (2) Mouse (2)
Tag:	His (5) Tag Free (3) Fc (2) Flag (1)
Source:	HEK293 (2) P. pastoris (1) E. coli (6)

Cat. No.	Product Name	Species	Source

HY-P7232

Leptin Protein, Human rHuLeptin; obesity protein; OB	Human	E. coli
Leptin Protein, Human is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P7233

Leptin Protein, Rat rRtLeptin; obesity protein (OB)	Rat	E. coli
Leptin Protein, Rat is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P7232A

Leptin Protein, Human (His)
rHuLeptin; obesity protein; OB
Human E. coli

HY-P7233A

Leptin Protein, Rat (His) rRtLeptin; obesity protein (OB)	Rat	E. coli
Leptin Protein, Rat is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P70704

Leptin Protein, Mouse Leptin; Obese Protein; obesity Factor; LEP; OB; OBS	Mouse	E. coli
Leptin Protein, Mouse is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.

HY-P70704A

Leptin Protein, Mouse (His)
Leptin; Obese Protein; obesity Factor; LEP; OB; OBS
Mouse E. coli
HY-P70181

Leptin Protein, Carassius auratus (P.pastoris, His)
rCaLeptin, His; Leptin; Obese Protein; obesity Factor; LEP; OB; OBS
Others P. pastoris
HY-P72471

Siglec-5 Protein, Human (HEK293, Fc)
Sialic acid-binding Ig-like lectin 5; Siglec-5; CD33 antigen-like 2; obesity-binding protein 2; OB-BP2; CD170
Human HEK293
HY-P71023

Siglec-5 Protein, Human (HEK293, His-Flag-Fc)
Sialic acid-binding Ig-like lectin 5; Siglec-5; CD33 antigen-like 2; obesity-binding protein 2; OB-BP2; CD170
Human HEK293

Cat. No.	Product Name

HY-F0004S

β-Nicotinamide mononucleotide-d4

β-Nicotinamide mononucleotide-d₄ is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

HY-W015464S1

N-Isovaleroylglycine-d2
N-Isovaleroylglycine-d₂ is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-W015464S

N-Isovalerylglycine-d9
N-Isovalerylglycine-d₉ is the deuterium labeled N-Isovaleroylglycine. N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity.

HY-107542S2

Oleoylethanolamide-d2
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S

Oleoylethanolamide-d4
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-15206S

Glyburide-d11

Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S1

Glyburide-d3

Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-B1779S3

Sucrose-d14
Sucrose-d₁₄ is the deuterium labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preferen

HY-B1779S5

Sucrose-13C6
Sucrose-¹³C₆ is the ¹³C labeled Sucrose[1]. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al[2].

HY-117275S1

Meclofenamic acid-13C6
Meclofenamic acid-¹³C₆ is the ¹³C₆ labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.

HY-117275S

Meclofenamic acid-d4
Meclofenamic acid-d₄ is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker[1][2][3].

HY-18260S1

Bisphenol A-d6

Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].

HY-18260S

Bisphenol A-d16

Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S4

Bisphenol A-d4

Bisphenol A-d₄ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S5

Bisphenol A-d4-1

Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S3

Bisphenol A-4d

Bisphenol A-d₈ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].

HY-N0055S

Chlorogenic acid-13C3

Chlorogenic acid-¹³C₃ (Heriguard-¹³C₃; NSC-407296-¹³C₃) is ¹³C- and ¹⁵N-labeled Chlorogenic acid (HY-N0055). Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb.. It plays several important and therapeutic roles such as antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension.

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

Cat. No.	Product Name	Application	Reactivity

HY-P80680

FTO Antibody FTO; KIAA1752; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein	WB, IHC-P	Human
FTO Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 58 kDa, targeting to FTO. It can be used for WB,IHC-P assays with tag free, in the background of Human.

obesity

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products